All PlansAdministrativeHigh impact
Voluntary nationwide recall: Atovaquone (Bionpharma – September)
UPMC Health Plan·Pharmacy, Infectious Disease, Internal Medicine +2 more·Pharmacy
Effective date
Sep 17, 2024
We identified it
Aug 7, 2026
Summary
Bionpharma Inc. is recalling Atovaquone Oral Suspension (750 mg/mL), lot 2310083, due to Cohnella bacteria contamination that poses serious health risks. The billing team must identify patients who received this specific lot, coordinate with providers and pharmacies to halt use, and manage any claim adjustments or reversals related to this contaminated medication.
Action Required
Immediately: (1) Billing team must identify all claims processed for Atovaquone Oral Suspension, 750 mg/mL (HCPCS J7971) where the service date falls within the recall period (on or after lot 2310083 manufacturing/distribution date). (2) Coordinate with providers and pharmacy to confirm which patients received the recalled lot 2310083. (3) For affected patients, prepare to reverse or adjust claims as directed by the plan and provider. (4) Flag any pending claims for this medication pending lot verification before processing. (5) Document all communications and claim actions in patient records. (6) Communicate recall information to provider offices and front desk staff to alert patients at point of contact. Contact Bionpharma at 1-888-235-2466 (TTY: 711, Mon-Fri 9am-5pm EST) or visit FDA website for lot verification. Failure to identify and manage these claims may result in billing for contaminated products and potential liability.